Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without offering specific guidance. They emphasized the importance of their current projects.
Management did not provide specific guidance for future performance.
The company is focusing on its ongoing projects and research.
Biocryst Pharmaceuticals reported a loss of $0.33 per share, which disappointed investors. The stock dropped by over 21% in response, reflecting concerns about the company's financial health and lack of guidance. Investors are likely worried about the absence of revenue figures and future performance expectations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ECHOSTAR CORP Class A
Aug 4, 2008